Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 68
Healthy volunteers: yes

Brief summary:
The study involves a single dose of LY3143753 or LY3185643, given as an injection into the abdomen. The study will evaluate the effects of the LY3143753 or LY3185643 on your body. The study is approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to the start of the study. This study involves Part A (LY3143753) and Part B (LY3185643). Participants may only enroll in one part and at one dose level.

Detailed description:

Arms:
arm 1: Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1 arm 2: Single SC injection of ascending doses of LY3185643 on Day 1 arm 3: Single SC injection of normal saline on Day 1 arm 4: Single SC injection on Day 1 arm 5: Single SC injection of normal saline on Day 1

Interventions: intervention 1: LY3143753 (Part A) intervention 2: LY3185643 (Part B) intervention 3: Placebo (Part A and Part B) intervention 4: rGlucagon (Part B)
Intervention descriptions: intervention 1: Administered via SC injection intervention 2: Administered via SC injection intervention 3: Administered via SC injection intervention 4: Administered via SC injection

Protocol document: